Strategic Integration of In Vivo Cardiovascular Models During Lead Optimization: Predictive Value of 4 Models Independent of Species, Route of Administration, and Influence of Anesthesia

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of Cardiovascular Pharmacology

• Publication date

  2012-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/FJC.0b013e31824485ddPMID 22179024
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical Trials Update

  2021cited by this paper
• Clinical Trials Update AHA Congress 2010

  2011cited by this paper
• Safety of anacetrapib in patients with or at high risk for coronary heart disease.

  2010cited by this paper
• Cardiac autonomic profile in rheumatoid arthritis and systemic lupus erythematosus

  2010cited by this paper
• Repeated dosing of ABT‐102, a potent and selective TRPV1 antagonist, enhances TRPV1‐mediated analgesic activity in rodents, but attenuates antagonist‐induced hyperthermia

  2009cited by this paper
• Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial

  2009cited by this paper
• A comparison of pharmacologic and spontaneous baroreflex methods in aging and hypertension

  2009cited by this paper
• The future of drug safety testing: expanding the view and narrowing the focus.

  2009cited by this paper
• Cardiovascular Effects of Torcetrapib in Conscious and Pentobarbital-anesthetized Dogs

  2009influential reference
• Effect of the Multitargeted Receptor Tyrosine Kinase Inhibitor, ABT-869 [N-(4-(3-Amino-1H-indazol-4-yl)phenyl)-N′-(2-fluoro-5-methylphenyl)urea], on Blood Pressure in Conscious Rats and Mice: Reversal with Antihypertensive Agents and Effect on Tumor Growth Inhibition

  2009cited by this paper
• ETA Receptor Blockade With Atrasentan Prevents Hypertension With the Multitargeted Tyrosine Kinase Inhibitor ABT-869 in Telemetry-instrumented Rats

  2009cited by this paper
• Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs.

  2008cited by this paper
• Metabolism, Pharmacokinetics, and Excretion of a Cholesteryl Ester Transfer Protein Inhibitor, Torcetrapib, in Rats, Monkeys, and Mice: Characterization of Unusual and Novel Metabolites by High-Resolution Liquid Chromatography-Tandem Mass Spectrometry and 1H Nuclear Magnetic Resonance

  2008cited by this paper
• Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone

  2008cited by this paper
• Effects of torcetrapib in patients at high risk for coronary events.

  2007cited by this paper
• Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.

  2007cited by this paper
• Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial.

  2007cited by this paper
• Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia

  2007cited by this paper
• Effect of torcetrapib on the progression of coronary atherosclerosis.

  2007cited by this paper
• Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin.

  2006cited by this paper
• Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels.

  2006cited by this paper
• Optimization of chromone-2-carboxamide melanin concentrating hormone receptor 1 antagonists: assessment of potency, efficacy, and cardiovascular safety.

  2006cited by this paper
• Screening for cardiovascular safety: a structure-activity approach for guiding lead selection of melanin concentrating hormone receptor 1 antagonists.

  2006cited by this paper
• Pharmacological Characterization of the Novel Dihydropyridine Potassium Channel Opener, (9R)-9-(3-Iodo-4-methylphenyl)-5,9-dihydro-3H-furo[3,4-b]pyrano[4,3-e]pyridine-1,8(4H,7H)-dione (A-325100), and the Regulation of Cardiovascular Function in Conscious and Anesthetized Beagle Dogs

  2005cited by this paper
• Baroreflex Sensitivity Is Reduced in Depression

  2005cited by this paper
• Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research.

  2005cited by this paper
• Raising High-Density Lipoprotein in Humans Through Inhibition of Cholesteryl Ester Transfer Protein: An Initial Multidose Study of Torcetrapib

  2004cited by this paper
• (−)-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide (A-278637), a Novel ATP-Sensitive Potassium Channel Opener: Hemodynamic Comparison to ZD-6169, WAY-133537, and Nifedipine in the Anesthetized Canine

  2004cited by this paper
• In vivo canine model comparison of cardiohemodynamic and electrophysiological effects of a new antipsychotic drug aripiprazole (OPC-14597) to haloperidol.

  2001cited by this paper
• Time and frequency domain estimates of spontaneous baroreflex sensitivity provide early detection of autonomic dysfunction in diabetes mellitus

  1997cited by this paper
• Arterial baroreceptor-cardiac reflex sensitivity in the elderly.

  1996cited by this paper
• Assessment of baroreceptor-cardiac reflex sensitivity using time domain analysis in patients with IDDM and the relation to left ventricular mass index

  1996cited by this paper
• Conscious State Comparisons of the Effects of the Inhalation Anesthetics and Diltiazem, Nifedipine, or Verapamil on Specialized Atrioventricular Conduction Times in Spontaneously Beating Dog Hearts

  1988cited by this paper
• Origin of tonic GABAergic inputs to vasopressor neurons in the subretrofacial nucleus of the rabbit.

  1988cited by this paper

• Discovery of Orally Efficacious Bridged Piperazines as smTNF Modulators.

  2025cites this paper
• Evaluation of the translation of multiple cardiovascular regulatory mechanisms in the anesthetized dog.

  2024cites this paper
• The Novel, Clinical-Stage Soluble Guanylate Cyclase Activator BI 685509 Protects from Disease Progression in Models of Renal Injury and Disease

  2022cites this paper
• Drug-induced QT prolongation: Concordance of preclinical anesthetized canine model in relation to published clinical observations for ten CiPA drugs.

  2020cites this paper
• Social-housing and use of double-decker cages in rat telemetry studies.

  2019cites this paper
• The evaluation of drug-induced changes in left ventricular function in pentobarbital-anesthetized dogs.

  2018cites this paper
• Physical Properties and Effect in a Battery of Safety Pharmacology Models for Three Structurally Distinct Enteric Polymers Employed as Spray-Dried Dispersion Carriers

  2016cites this paper
• Cardiovascular safety pharmacology studies in dogs enabled for a poorly soluble molecule using spray-dried dispersion: Impact on lead selection.

  2016cites this paper
• Torcetrapib and Dalcetrapib Safety: Relevance of Preclinical In Vitro and In Vivo Models

  2015cites this paper
• G Protein–Coupled Bile Acid Receptor 1 Stimulation Mediates Arterial Vasodilation through a KCa1.1 (BKCa)–Dependent Mechanism

  2014cites this paper
• Cross-species scaling of cardiovascular safety pharmacology using PKPD modelling and simulation

  2013cites this paper
• The Clinically-tested S1P Receptor Agonists, FTY720 and BAF312, Demonstrate Subtype-Specific Bradycardia (S1P1) and Hypertension (S1P3) in Rat

  2012cites this paper